Volume 2, Number 2—April 1996
Dispatch
Improved Serodiagnostic Testing for Lyme Disease: Results of a Multicenter Serologic Evaluation
Table 2
Test sensitivity of laboratories demonstrating a test specificity of 98%
| Sensitivity, % (positive samples/total) | |||
|---|---|---|---|
| Clinical Manifestations |
Laboratory 1 |
Laboratory 2 |
Laboratory 3 |
| Erythema migrans, all | 59 (55/94) | 60 (56/94) | 66 (62/94) |
| Acute phasea | 65 (11/17) | 65 (11/17) | 76 (13/17) |
| Convalescent phaseb | 57 (44/77) | 58 (45/77) | 64 (49/77) |
| Carditis | 100 (2/2) | 100 (2/2) | 100 (2/2) |
| Lyme arthritisc | 89 (58/65) | 95 (62/65) | 92 (60/65) |
| Neurologic, all | 85 (28/33) | 88 (29/33) | 91 (30/33) |
| Early | 63 (5/8) | 63 (5/8) | 75 (6/8) |
| Late | 91 (10/11) | 100 (11/11) | 91 (10/11) |
| Late and arthritis |
93 (13/14) |
93 (13/14) |
100 (14/14) |
| Total | 74 (143/194) | 77 (149/194) | 79 (154/194) |
a <=30 days from onset of erythema migrans to blood collection.
b > 30 days from onset of erythema migrans to blood collection.
c Without neurologic signs or symptoms.
